예측 기간
시장 규모(기준 연도)
시장 규모(예측 연도)
연평균 성장률북미 국소 약물 전달 시장, 제품 유형(약물 전달 제형 및 약물 전달 장치 ), 전달 기술(이온 전달법, 소노포레시스, 레이저 소거법, 고주파 소거법, 자기 전달법, 전기 천공법 및 기타), 유형(클렌징제, 보호제, 보습제, 건조제, 가려움 방지제, 항염제, 항감염제, 각질 용해제 및 기타), 세대(1세대 경피 전달 시스템, 2세대 경피 전달 시스템 및 3세대 경피 전달 시스템), 구매 방식(처방 및 일반 의약품), 적응증(피부 질환, 안과 질환, 통증 관리, 신경외과 질환, 호르몬 요법, 금연 및 기타), 투여 경로(피부, 안과, 직장, 질, 비강 및 기타), 최종 사용자(병원, 전문 센터, 가정 의료, 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) - 업계 동향 및 2030년 예측.
북미 국소 약물 전달 시장 분석 및 통찰력
북미 국소 약물 전달 시장은 북미에서 피부 질환과 안과 질환의 유병률이 증가함에 따라 증가하고 있습니다. 또한, 의료비 지출이 증가하고 진단 및 피부 질환 치료에 대한 인식이 높아지면서 시장 가치 성장에도 기여하고 있습니다. 따라서 피부과 처방 기반 약물에 대한 수요가 증가하고 있습니다. 국소 약물 전달에 대한 연구 개발이 증가하면서 국소 약물 전달 시장에서 새로운 기회가 창출되고 있습니다.
Data Bridge Market Research는 북미 국소 약물 전달 시장이 2030년까지 80,484.97백만 달러에 도달할 것으로 예상되며, 예측 기간 동안 CAGR은 6.8%입니다. 피부과 처방 기반 약물에 대한 수요 증가. 국소 약물 전달에 대한 연구 개발이 증가하면서 국소 약물 전달 시장에서 새로운 기회가 창출되고 있습니다. 이 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2023년부터 2030년까지 |
|
기준 연도 |
2022 |
|
역사적 연도 |
2021 (2020-2015까지 사용자 정의 가능) |
|
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시 |
|
다루는 세그먼트 |
Product Type (Drug Delivery Formulations and Drug Delivery Devices), Delivery Techniques (Ionotophoresis, Sonophoresis, Laser Ablation, Radio Frequency Ablation, Magnetophoresis, Electroporation And Others), Type (Cleansing Agents, Protective Agents, Moisturizing Agents, Drying Agents, Anti-Itch Agents, Anti-Inflammatory Agents, Anti-Infective Agents, Keratolytics, and Others), Generation (First Generation Transdermal Delivery Systems, Second Generation Transdermal Delivery Systems and Third Generation Transdermal Delivery Systems), Mode of Purchase (Prescription and Over The Counter), Indication (Dermatological Disorders, Ophthalmic Disorders, Pain Management, Neurosurgical Disorders, Hormonal Therapy, Smoking Cessation and Others), Route of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal and Others), End User (Hospitals, Specialty Centers, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) |
|
Countries Covered |
U.S., Canada, Mexico |
|
Market Players Covered |
CRESCITA THERAPEUTICS INC., Cipla Inc., Glenmark, Bausch Health Companies, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Viatris Inc., NITTO DENKO CORPORATION, LTS Lohmann Therapy Systems AG, Procter & Gamble, ANI Pharmaceuticals, Inc., Corium, Inc., Medherant Limited., Purdue Pharmaceuticals L.P., AbbVie Inc., GSK plc., 3M., Agile Therapeutics, Tapemark, tesa Labtec GmbH, Noven Pharmaceuticals, Inc. among others |
Market Definition
Topical drug delivery is considered one of the most effective methods due to its optimal therapeutic benefits. The desired therapeutic effect and unwanted side effect of a drug are both determined by the concentration of the drug at the site of action. The concentration of the drug is determined by the dosage form and absorption of the drug at the site of action. The growth of this market is attributed to the rising prevalence of diabetes, the growing number of burn cases, escalating prevalence of dermal diseases, and technological developments in topical drug delivery systems. In addition, the major consumers of topical drug delivery systems are specialty clinics and hospitals. Some other consumers include diagnostic centers and home care centers.
North America Topical Drug Delivery Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- HIGH PREVALENCE OF SKIN DISEASES
The prevalence of skin diseases is expanding at a quicker rate, and it is becoming a North America problem. The enormous burden of various skin diseases and conditions makes drug administration crucial. The increased prevalence of skin conditions positively impacts the North America topical drug delivery market. As a result, the market is estimated to show lucrative growth over the forecasted period. The increasing incidences of skin infections such as eczema, psoriasis, and minor ailments, including acne, are the most significant factors driving the growth of this market.
- RISING COMPANY ACTIVITIES IN DEVELOPING PRODUCTS AND INCREASING PRODUCT LAUNCHES
As various skin diseases are on the urge, the need for topical drugs is rapidly increasing. Various companies are taking initiatives to develop new products and launch them in the market. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market.
- HIGH INCIDENCE OF BURN INJURIES
Burns are tissue damage that results from heat, overexposure to the sun or other radiation, or chemical or electrical contact. Burns can be minor medical problems or life-threatening emergencies. High incidences of burn injuries are seen in various regions across the globe.
Restraints
continuous irritation on THE skin and allergies caused by topical drugs
Many topical formulations are available over the counter, including antibacterial and antifungal preparations, anti-inflammatory and pain relief preparations, and cleansing and moisturizing agents. Topical corticosteroids are used in many inflammatory rashes. However, in some cases, topical corticosteroid sensitivity produces allergic reactions.
Usually, this is seen as a failure to cure dermatitis or to worsen existing dermatitis treated with corticosteroids. Very rarely, corticosteroid allergy may appear as an eczematous rash in a completely different area of the body from original dermatitis.
Some topical antibodies may also cause contact allergies, such as bacitracin, which is used to prevent minor skin injuries such as cuts, scrapes, and burns. Benzocaine and salicylate are some active ingredients in topical formulations which causes allergies. These allergies caused by such drugs can be diagnosed by a patch test that can detect contact allergens.
discontinued product recalls in the u.s.
Product recall is the most common threat for any business or any market. It has a serious negative impact on the market, such as decreased market size and a decline in revenue for the company, among others. In the topical drugs market, various products are recalled due to some defect in batch or after getting banned by the FDA.
Opportunity
Extensive R&D activities in dermatology drugs
Rising R&D activities for developing innovative and highly efficient drugs are expected to boost market growth. There is a rising demand for therapies and a deeper understanding of disease pathways, genetic discoveries, antibody drug development, novel targets, advanced delivery technologies, and diagnostic technologies which can be utilized in translational research and clinic.
The increase in the burden of skin-related diseases with unmet medical needs has increased the demand for new innovative drugs for treating infectious skin diseases, pigmentation disorders, and inflammatory/autoimmune disorders, which has increased the research and development activities for dermatological drugs in order to bring new drugs to market.
Challenge
Stringent Regulation for product approval
Regulation of drugs and topical ointments plays a significant role in healthcare. Achieving the requisite approval for legal selling medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or considered, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, among others, are of significant importance for treating various diseases. But their approval and marketing in multiple regions across North America require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.
Post-COVID-19 Impact on North America Topical Drug Delivery Market
The pharmaceutical industry has been severely affected by the COVID-19 pandemic. Lockdowns imposed due to the epidemic have disrupted the supply of raw materials from manufacturing centers such as India and China. This slowed drug development and production, severely affecting companies that relied heavily on outsourcing. Initially, the entire pharmaceutical ecosystem was disrupted. In addition, regulatory agencies had to draft and draft new laws to ensure maximum patient safety after using drugs. After the shutdowns ended, the pharmaceutical industry gained steam, especially due to the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The growing demand for these drugs boosted the turnover of some companies.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology in the topical drug delivery market.
Recent Developments
- In December 2022, GSK plc announced new 48-week data from the MOMENTUM phase III trial were released, showing that most patients treated with investigational momelotinib maintained their responses across critical clinical measures, such as the Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR), in myelofibrosis patients who had previously received treatment with an approved Janus kinase (JAK) inhibitor. In addition, fresh MOMENTUM studies revealed that the TI response to momelotinib at week 24 was related to overall survival. This has helped the company to expand its business in the market
- In January 2022, Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced a new alliance with Afaxys Pharma, LLC to promote Twirla (levonorgestrel and ethinyl estradiol) transdermal system. This has helped the company to increase its North America presence in the market
North America Topical Drug Delivery Market Scope
North America topical drug delivery market is segmented into product type, delivery technique, type, generation, mode of purchase, indication, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
North America Topical Drug Delivery Market, By Product Type
- Drug Delivery Formulations
- Drug Delivery Devices
On the basis of product type, the North America laboratory hoods and enclosure market is segmented into drug delivery formulations and drug delivery devices.
North America Topical Drug Delivery Market, By Delivery Techniques
- Sonophoresis
- Electroporation
- Laser Ablation
- Ionotophoresis
- Radio Frequency Ablation
- Magnetophoresis
- Others
On the basis of delivery techniques, the North America laboratory hoods and enclosure market is segmented into ionotophoresis, sonophoresis, laser ablation, radio frequency ablation, magnetophoresis, electroporation and others.
North America Topical Drug Delivery Market, By Type
- Cleansing Agents
- Protective Agents
- Moisturizing Agents (Emollients)
- Drying Agents
- Anti-Itch Agents
- Anti-Inflammatory Agents
- Anti-Infective Agents
- Kerolytics
- Others
On the basis of type, the North America laboratory hoods and enclosure market is segmented into cleansing agents, protective agents, moisturizing agents, drying agents, anti-itch agents, anti-inflammatory agents, anti-infective agents, keratolytics, and others.
North America Topical Drug Delivery Market, By Generation
- First-Generation Transdermal Delivery Systems
- Second-Generation Transdermal Delivery Systems
- Third-Generation Transdermal Delivery Systems
On the basis of generation, the North America laboratory hoods and enclosure market is segmented into first generation transdermal delivery systems, second generation transdermal delivery systems and third generation transdermal delivery systems.
North America Topical Drug Delivery Market, By Mode of Purchase
- 처방
- 카운터 위
구매 방식을 기준으로 북미 실험실 후드 및 인클로저 시장은 처방전이 필요한 제품과 처방전 없이 구입할 수 있는 제품으로 구분됩니다.
북미 국소 약물 전달 시장, 지표별
- 피부과 질환
- 안과 질환
- 통증 관리
- 신경계 질환
- 호르몬 치료
- 흡연 중단
- 기타
북미 실험실 후드 및 인클로저 시장은 적응증을 기준으로 피부과 질환, 안과 질환, 통증 관리, 신경외과 질환, 호르몬 치료, 금연 및 기타로 구분됩니다.
북미 국소 약물 전달 시장, 투여 경로별
- 피부
- 안과
- 직장
- 질의
- 비강
- 기타
투여 경로를 기준으로 북미 실험실 후드 및 인클로저 시장은 피부용, 안과용, 직장용, 질용, 비강용 및 기타용으로 구분됩니다.
북미 국소 약물 전달 시장, 최종 사용자별
- 병원
- 홈 헬스케어
- 전문 센터
- 기타
북미 실험실 후드 및 인클로저 시장은 최종 사용자를 기준으로 병원, 전문 센터, 가정 의료 및 기타로 구분됩니다.
북미 국소 약물 전달 시장, 유통 채널별
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타
북미 실험실 후드 및 인클로저 시장은 유통 채널을 기준으로 병원 약국, 소매 약국, 온라인 약국 및 기타로 구분됩니다.
북미 국소 약물 전달 시장 지역 분석/통찰력
북미 국소 약물 전달 시장을 분석하고, 제품 유형, 전달 기술, 유형, 세대, 구매 방식, 적응증, 투여 경로, 최종 사용자 및 유통 채널에 대한 시장 규모 정보를 제공합니다.
이 시장 보고서에서 다루는 국가로는 미국, 캐나다, 멕시코가 있습니다.
북미는 GDP가 높은 가장 큰 소비자 시장에 주요 시장 참여자가 존재하기 때문에 우위를 점할 것으로 예상됩니다. 미국은 Healthcare IT의 기술 발전으로 인해 성장할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 국내 시장의 개별 시장 영향 요인과 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 북미 국소 약물 전달 시장 점유율 분석
북미 국소 약물 전달 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 회사가 북미 국소 약물 전달 시장에 집중하는 것과만 관련이 있습니다.
북미 국소 약물 전달 시장의 주요 기업으로는 CRESCITA THERAPEUTICS INC., Cipla Inc., Glenmark, Bausch Health Companies, Inc., Merck & Co., Inc., Novartis AG, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Viatris Inc., NITTO DENKO CORPORATION, LTS Lohmann Therapy Systems AG, Procter & Gamble, ANI Pharmaceuticals, Inc., Corium, Inc., Medherant Limited., Purdue Pharmaceuticals LP, AbbVie Inc., GSK plc., 3M., Agile Therapeutics, Tapemark, tesa Labtec GmbH, Noven Pharmaceuticals, Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TOPICAL DRUG DELIVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 INDUSTRIAL INSIGHTS
6 PIPELINE ANALYSIS
7 EPIDEMIOLOGY
8 REGULATORY FRAMEWORK
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 HIGH PREVALENCE OF SKIN DISEASES
9.1.2 RISING COMPANY ACTIVITIES IN DEVELOPING PRODUCTS AND INCREASING PRODUCT LAUNCHES
9.1.3 HIGH INCIDENCE OF BURN INJURIES
9.2 RESTRAINTS
9.2.1 CONTINUOUS IRRITATION ON THE SKIN AND ALLERGIES CAUSED BY TOPICAL DRUGS
9.2.2 DISCONTINUED PRODUCT RECALLS IN THE U.S.
9.3 OPPORTUNITIES
9.3.1 EXTENSIVE R&D ACTIVITIES IN DERMATOLOGY DRUGS
9.3.2 INCREASING INVESTMENT IN BIOLOGICS AND BIOSIMILARS
9.4 CHALLENGES
9.4.1 STRINGENT REGULATION FOR PRODUCT APPROVAL
9.4.2 ALTERNATIVE TO TOPICAL DRUGS FOR TREATMENT
10 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 DRUG DELIVERY FORMULATIONS
10.2.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
10.2.1.1 OINTMENTS
10.2.1.2 CREAM
10.2.1.3 GELS
10.2.1.4 LOTIONS
10.2.1.5 PASTES
10.2.1.6 FOAM
10.2.1.7 OTHERS
10.2.2 LIQUID TOPICAL DRUG DELIVERY
10.2.2.1 SOLUTIONS
10.2.2.2 SUSPENSION
10.2.2.3 OTHERS
10.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
10.2.3.1 POWDER
10.2.3.2 SUPPOSITORIES
10.2.3.3 OTHERS
10.3 DRUG DELIVERY SYSTEMS
10.3.1 TRANSDERMAL PATCHES
10.3.1.1 PASSIVE NON-INVASIVE PATCHES
10.3.1.1.1 RECTANGULAR
10.3.1.1.2 SQUARE
10.3.1.1.3 OTHERS
10.3.2 RESERVOIR
10.3.2.1 NITROGLYCERINE
10.3.2.2 OESTRADIOL
10.3.2.3 CLONIDINE
10.3.2.4 SCOPOLAMINE
10.3.2.5 OTHERS
10.3.3 MATRIX
10.3.3.1 NICOSTOP PATCH
10.3.3.2 ANGIDERM PATCH
10.3.3.3 OTHERS
10.3.4 DRUG IN-ADHESIVE
10.3.4.1 MULTI
10.3.4.2 SINGLE
10.3.5 NEXT GENERATION PATCHES
10.3.5.1 DISPOSABLE NFC BIOMARKER PATCHES
10.3.5.2 ZP-PTH RAPID DELIVERY PATCH
10.3.5.3 OTHERS
10.3.6 ACTIVE PATCHES
10.3.6.1 MICRONEEDLE PATCH
10.3.6.2 FENTANYL TRANSDERMAL PATCH
10.3.6.3 GLYCERALTRINITRATE (GTN) TRANSDERMAL PATCH
10.3.6.4 OTHERS
10.3.7 MINIMALLY INVASIVE PATCHES
10.3.7.1 GELATIN METHACRYLOYL MICRONEEDLE PATCH
10.3.7.2 UV PATCH
10.3.7.3 OTHERS
10.3.8 VAPOR PATCHES
10.3.8.1 VICKS VAPOR PATCH
10.3.8.2 NAZO VAPOR PATCH
10.3.8.3 RUNBUGZ VAPOR PATCH
10.3.8.4 OTHERS
10.3.9 NANOEMULSION GEL
10.3.9.1 MICROSPONGES
10.3.9.2 OTHERS
11 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES
11.1 OVERVIEW
11.2 IONOTOPHORESIS
11.3 SONOPHORESIS
11.4 LASER ABLATION
11.5 RADIO FREQUENCY ABLATION
11.6 MAGNETOPHORESIS
11.7 ELECTROPORATION
11.8 OTHERS
12 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION
13.1 OVERVIEW
13.2 DERMATOLOGICAL DISORDERS
13.2.1 ACNE
13.2.2 ECZEMA
13.2.3 RINGWORM
13.2.4 ICHTHYOSIS
13.2.5 WARTS
13.2.6 PSORIASIS
13.2.7 ATOPIC DERMATITIS
13.2.8 PERIORAL DERMATITIS
13.2.9 PRESSURE SORES
13.2.10 ROSACEA
13.2.11 ATHLETE’S FOOT
13.2.12 OTHERS
13.3 OPHTHALMIC DISORDERS
13.3.1 CONJUNCTIVITIS
13.3.2 KERATITIS
13.3.3 EYE REDNESS
13.3.4 GLAUCOMA
13.3.5 BLEPHARITIS
13.3.6 IRITIS
13.3.7 MACULAR EDEMA
13.3.8 PUPILLARY DILATION
13.3.9 RETINOPATHY
13.3.10 STRABISMUS
13.3.11 OTHER
13.4 PAIN MANAGEMENT
13.5 HORMONAL THERAPY
13.6 NEUROLOGICAL DISORDERS
13.7 SMOKING CESSATION
13.8 OTHERS
14 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 DERMAL
14.3 OPHTHALMIC
14.4 RECTAL
14.5 VAGINAL
14.6 NASAL
14.7 OTHERS
15 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE
15.1 OVERVIEW
15.2 CLEANSING AGENTS
15.3 PROTECTIVE AGENTS
15.4 MOISTURIZING AGENTS (EMOLLIENTS)
15.5 DRYING AGENTS
15.6 ANTI-ITCH AGENTS
15.6.1 MENTHOL
15.6.2 PRAMOXINE
15.6.3 DOXEPIN
15.6.4 OTHERS
15.7 ANTI- INFLAMMATORY AGENTS
15.7.1 CORTICOSTEROIDS
15.7.2 CHAMOMILE
15.7.3 CALENDULA
15.7.4 OTHERS
15.8 ANTI-INFECTIVE AGENTS
15.8.1 TOPICAL ANTIBIOTICS
15.8.1.1 CLINDAMYCIN
15.8.1.2 ERYTHROMYCIN
15.8.1.3 METRONIDAZOLE
15.8.1.4 MUPIROCIN
15.8.1.5 BACITRACIN
15.8.1.6 POLYMYXIN
15.8.1.7 OTHERS
15.8.2 TOPICAL ANTIFUNGALS
15.8.2.1 KETOCONAZOLE
15.8.2.2 MICONAZOLE
15.8.2.3 ECONAZOLE
15.8.2.4 NYSTATIN
15.8.2.5 CICLOPIROX
15.8.2.6 TOLNAFTATE
15.8.2.7 TERBINAFINE
15.8.2.8 CLOTRIMAZOLE
15.8.2.9 OTHERS
15.8.3 NON-ANTIBIOTIC TOPICAL ANTISEPTICS
15.8.3.1 IODINE SOLUTIONS
15.8.3.2 GENTIAN VIOLET
15.8.3.3 ZINC PYRITHIONE
15.8.3.4 SILVER PREPARATIONS
15.8.3.5 OTHERS
15.9 KERATOLYTICS
15.9.1 SALICYLIC ACID
15.9.2 UREA
15.9.3 OTHERS
15.1 OTHERS
16 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION
16.1 OVERVIEW
16.2 SECOND-GENERATION TRANSDERMAL DELIVERY SYSTEMS
16.3 FIRST-GENERATION TRANSDERMAL DELIVERY SYSTEMS
16.4 THIRD-GENERATION TRANSDERMAL DELIVERY SYSTEMS
17 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 SPECIALTY CENTRES
17.4 HOSPITAL
17.5 OTHERS
18 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY
19.1 U.S.
19.2 CANADA
19.3 MEXICO
20 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 CRESCITA THERAPEUTICS INC
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 GSK PLC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 PRODUCT PORTFOLIO
22.2.4 RECENT DEVELOPMENT
22.3 AGILE THERAPEUTICS
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 PRODUCT PORTFOLIO
22.3.4 RECENT DEVELOPMENT
22.4 PFIZER INC.
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 PRODUCT PORTFOLIO
22.4.4 RECENT DEVELOPMENT
22.5 ABBVIE INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENT
22.6 ANI PHARMACEUTICALS, INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 BAUSCH HEALTH COMPANIES INC.
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENT
22.8 BAYER AG
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 CIPLA INC.
22.9.1 COMPANY SNAPSHOT
22.9.2 REVENUE ANALYSIS
22.9.3 PRODUCT PORTFOLIO
22.9.4 RECENT DEVELOPMENTS
22.1 GLENMARK
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENT
22.11 HISAMITSU PHARMACEUTICAL CO., INC.
22.11.1 COMPANY SNAPSHOT
22.11.2 PRODUCT PORTFOLIO
22.11.3 RECENT DEVELOPMENT
22.12 LTS LOHMANN THERAPY SYSTEMS AG
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENT
22.13 MEDHERANT LIMITED.
22.13.1 COMPANY SNAPSHOT
22.13.2 PRODUCT PORTFOLIO
22.13.3 RECENT DEVELOPMENT
22.14 MERCK & CO., INC.
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENT
22.15 3M.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENT
22.16 NITTO DENKO CORPORATION.
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 NOVARTIS AG
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENT
22.18 NOVEN PHARMACEUTICALS, INC.
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 PROCTER & GAMBLE
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENT
22.2 PURDUE PHARMACEUTICALS L.P.
22.20.1 COMPANY SNAPSHOT
22.20.2 PRODUCT PORTFOLIO
22.20.3 RECENT DEVELOPMENT
22.21 TAPEMARKTM
22.21.1 COMPANY SNAPSHOT
22.21.2 PRODUCT PORTFOLIO
22.21.3 RECENT DEVELOPMENT
22.22 TESA LABTEC GMBH
22.22.1 COMPANY SNAPSHOT
22.22.2 PRODUCT PORTFOLIO
22.22.3 RECENT DEVELOPMENT
22.23 VIATRIS INC.
22.23.1 COMPANY SNAPSHOT
22.23.2 REVENUE ANALYSIS
22.23.3 PRODUCT PORTFOLIO
22.23.4 RECENT DEVELOPMENT
23 QUESTIONNAIRE
24 RELATED REPORTS
표 목록
TABLE 1 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 6 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 8 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 10 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA DRUG DELIVERY SYSTEMS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 12 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA DRUG IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA NEXT GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA MINIMALLY INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA VAPOR PATCHES IN TOPICAL DRUG DELIVERY MARKET, PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 43 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 45 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 46 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 48 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 50 NORTH AMERICA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 76 U.S. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.S. DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 80 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 81 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 83 U.S. LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 84 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 86 U.S. SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 87 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 89 U.S. DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 90 U.S. TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.S. PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.S. RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 U.S. MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 U.S. DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.S. NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.S. ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 U.S. MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.S. VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.S. TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)
TABLE 100 U.S. TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 U.S. ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.S. ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 103 U.S. ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 104 U.S. TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 105 U.S. TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 106 U.S. NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 107 U.S. KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 108 U.S. TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)
TABLE 109 U.S. TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)
TABLE 110 U.S. TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 111 U.S. DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 112 U.S. OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 113 U.S. TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 114 U.S. TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 U.S. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 CANADA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 CANADA DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 120 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 121 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 123 CANADA LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 124 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 126 CANADA SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 127 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 129 CANADA DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 130 CANADA TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 CANADA PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 CANADA RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 133 CANADA MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 134 CANADA DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 CANADA NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 CANADA ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 CANADA MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 CANADA VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 CANADA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)
TABLE 140 CANADA TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 141 CANADA ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 142 CANADA ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 143 CANADA ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 CANADA TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 CANADA TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 146 CANADA NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 147 CANADA KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 CANADA TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)
TABLE 149 CANADA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)
TABLE 150 CANADA TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 151 CANADA DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 152 CANADA OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 153 CANADA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 154 CANADA TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 CANADA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 MEXICO TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 MEXICO DRUG DELIVERY FORMULATIONS IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 160 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 161 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 163 MEXICO LIQUID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 164 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 165 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 166 MEXICO SOLID TOPICAL DRUG DELIVERY IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 167 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 168 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, BY PRODUCT TYPE, 2021-2030 (MILLION UNITS)
TABLE 169 MEXICO DRUG DELIVERY SYSTEM IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)
TABLE 170 MEXICO TRANSDERMAL PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 MEXICO PASSIVE NON-INVASIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 MEXICO RESERVOIR IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 MEXICO MATRIX IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 174 MEXICO DRUG-IN-ADHESIVE IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 MEXICO NEXT-GENERATION PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 176 MEXICO ACTIVE PATCHES IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 177 MEXICO MINIMALLY INVASIVE PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 178 MEXICO VAPOR PATCH IN TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 179 MEXICO TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES, 2021-2030 (USD MILLION)
TABLE 180 MEXICO TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 181 MEXICO ANTI-ITCH AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 MEXICO ANTI-INFLAMMATORY AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 183 MEXICO ANTI-INFECTIVE AGENTS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 184 MEXICO TOPICAL ANTIBIOTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 185 MEXICO TOPICAL ANTIFUNGALS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 MEXICO NON-ANTIBIOTIC TOPICAL ANTISEPTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 187 MEXICO KERATOLYTICS IN TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 MEXICO TOPICAL DRUG DELIVERY MARKET, BY GENERATION, 2021-2030 (USD MILLION)
TABLE 189 MEXICO TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)
TABLE 190 MEXICO TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 191 MEXICO DERMATOLOGICAL DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 192 MEXICO OPHTHALMIC DISORDERS IN TOPICAL DRUG DELIVERY MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 193 MEXICO TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 194 MEXICO TOPICAL DRUG DELIVERY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 195 MEXICO TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SEGMENTATION
FIGURE 11 INCREASED HEALTHCARE SPENDING AND THE RISE IN THE PREVALENCE OF SKIN DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD
FIGURE 12 DRUG DELIVERY FORMULATIONS ARE EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET
FIGURE 14 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, 2022
FIGURE 19 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DELIVERY TECHNIQUES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, 2022
FIGURE 23 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, 2022
FIGURE 27 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, 2022
FIGURE 35 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 38 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, 2022
FIGURE 39 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, 2023-2030 (USD MILLION)
FIGURE 40 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, CAGR (2023-2030)
FIGURE 41 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 42 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, 2022
FIGURE 43 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: SNAPSHOT (2022)
FIGURE 51 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2022)
FIGURE 52 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE (2023-2030)
FIGURE 55 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
